In partnership with
December 2, 2025
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today we zero in on the quiet levers that decide who lasts: warning labels that still lag the science, courts that are tightening once-flexible gray zones, and lawmakers who are reshaping hemp and medical channels while most people look the other way.
Today’s edition is brought to you by You.com and AltIndex, two tools that help serious readers turn noise into usable signal; if you want your work in front of the same decision-makers, reply to this email and we will talk about advertising.
⚠️ Warning labels and shared standards
🏛️ Courts, zoning fights, and lender power
🧊 Hemp bans, medical pivots, and who gets squeezed
Strong habits beat lucky breaks
One major reason AI adoption stalls? Training.
AI implementation often goes sideways due to unclear goals and a lack of a clear framework. This AI Training Checklist from You.com pinpoints common pitfalls and guides you to build a capable, confident team that can make the most out of your AI investment.
What you'll get:
Key steps for building a successful AI training program
Guidance on overcoming employee resistance and fostering adoption
A structured worksheet to monitor progress and share across your organization
Start here — the day’s most important development, decoded for impact.
📌 What Happened: A new analysis from the American Enterprise Institute, amplified in STAT, argues that no U.S. adult-use jurisdiction currently requires a fully adequate set of health warnings on cannabis products. The AEI team scored state systems against 12 evidence-based elements, including child access, pregnancy and breastfeeding, impaired driving, mental health and psychosis risk, potency, font size, and placement. Nevada and California sit at the top of the board with seven or eight required elements, while a dozen jurisdictions, including Connecticut, D.C., New Jersey, Ohio, Rhode Island, and Vermont, earn failing marks for thin or fragmented schemes. Only a small handful of states require any mental health language, and only a couple require product-specific psychosis warnings for high-THC SKUs. The picture that emerges is less a national framework and more a set of local experiments around a psychoactive product that now travels in suitcases, social media, and supply chains that ignore state borders.
💡 Why It Matters: Warning labels are one of the few tools that every legal consumer sees, which makes their content feel like low-hanging fruit for public health. The AEI and Meek findings show real gaps: most states cover children, pregnancy, and impaired driving, yet very few speak plainly about psychosis, dependence, or the specific risks of high-potency concentrates, even as those products define the modern market. State programs also do not start from a clean sheet of paper. Many regulators inherit ballot text written to win a campaign, omnibus bills packed with local favors, and statutory language that bakes in phrases or symbols no neighboring jurisdiction uses. Nobody in that process is designing a nationwide system; they are trying to get their own program passed and keep it standing. The result on the package is a crowded panel that has to accommodate THC numbers, state seals, universal symbols, recycling marks, and legal disclaimers, with warnings squeezed into whatever space is left and read like one more block of compliance text. That clutter is why AEI and others now float federal baselines, not just to strengthen health messaging but to avoid a future where interstate commerce stalls because states are still arguing over synonyms and slightly different “universal” upside down or right-side-up triangles.
🧠 THC Group Take: Warning panels are one of the few places where this industry can prove it has learned from alcohol and tobacco instead of repeating their slowest lessons. A smart version of that future does not cram every study onto a two-by-two label; it prioritizes a short set of core warnings on the package, then sends everything else through tools like QR codes and dynamic landing pages that can carry evolving science, dosage guidance, and local resources without turning the box into fine print. That approach only works if the architecture behind it is shared, which means interoperable data standards for icons, text blocks, and QR payloads so a product can move from New Jersey to Ohio one day without needing a full redesign of its risk communication. Regulators gain more room for local politics once they agree on a common spine for symbols and messages, and operators save real money if they can print one panel that satisfies both state rules and eventual federal expectations. Warning labels aren’t sexy, but they do sit at the intersection of public health, branding, technology, and future interstate commerce. The programs that invest in clear standards now will be the ones that look prepared when Congress finally decides cannabis packaging belongs in the same chapter as cigarettes and spirits. Say it with me…standards matter!
Fast-moving headlines, flagged for what matters.
Gov. Tim Walz is already looking for a way around Congress’s new hemp THC ban, warning it would be very disruptive to Minnesota’s beverage and edibles market. He has been blunt that the federal language blindsided operators who just invested under the state’s new adult-use and hemp frameworks. House Majority Whip Tom Emmer and several Democrats in the delegation are now talking about a fix that could ride the Farm Bill or another must-pass bill. Their case leans on Minnesota’s age-gated, tested hemp system as proof that states can police this space without Washington pulling products off shelves. The real test will come when that delegation has to pick between floor speeches and concrete bill text before the November 2026 deadline snaps into place. (Marijuana Moment)
Kentucky commentators are defending Sen. Mitch McConnell’s hemp THC language as a course correction that drags the crop back to CBD, grain, and fiber and away from gas-station gummies. The op-ed leans on images of kids surrounded by THC candy and on the original 2018 Farm Bill rhetoric that never mentioned seltzers or mocktails. It sketches a coalition that runs from prohibitionists to slices of Big Alcohol to marijuana licensees who see hemp drinks as unfairly light-touch competition. Inside that frame, the 0.4 milligram total-THC cap becomes a tool to squeeze out intoxicating hemp while still claiming to stand with farmers. If this narrative hardens, Kentucky’s delegation will be able to say they saved hemp even as the acres that survive look more like a specialty crop than a replacement for tobacco. (Courier Journal (opinion))
THC cans are already living beside beer and seltzer in coolers while Congress debates whether they count as hemp or something closer to liquor. GreenState’s piece follows brands like Cann that treat the 2026 federal deadline as a one-year clock to lock in alcohol-style rules for drinks even if other hemp formats get squeezed. Farmers and full-spectrum CBD manufacturers warn that the same language could finish off supplement and oil markets that were already under strain. Trade groups and advocates, including Steve DeAngelo’s One Plant Alliance, argue for an age-gated, tested framework that keeps beverages and non-beverage SKUs under the same basic guardrails. The culture fight will be decided in the grocery aisles and taprooms where people already treat a THC drink like a light beer, and where any federal fix either blesses that reality or forces it back underground. (GreenState)
Texas regulators have tentatively added nine cannabis companies to the 10-year-old Compassionate Use Program, expanding the roster from three licensees to twelve and moving toward a statutory cap of fifteen. The new group, which includes Verano, Trulieve, PharmaCann and several lesser-known LLCs, will be allowed to cultivate, manufacture, distribute, and sell prescription-only THC products if they clear a final DPS evaluation. The expansion comes as TCUP serves about 116,000 patients and as more than 9,000 hemp retailers stare down a possible federal ban on consumable hemp by next November, a shift that could drive some consumers toward the medical channel. Patient advocates and standards groups are already flagging transparency concerns, warning that “mystery LLCs” with opaque ownership and thin compliance histories are a risky foundation for a program that wants to be seen as medicine rather than politics. Time will tell how hard DPS pushes on due diligence, ownership disclosure, and even basic labeling expectations before turning these conditional licenses into permanent footholds. (The Dallas Morning News)
Angel Bursch can drive from her Loonatixz Genetixz grow to her Grand Rapids dispensary in twenty minutes, yet she cannot legally move a single clone between them because almost no one in Minnesota is licensed to transport cannabis. As of late November, the Office of Cannabis Management had issued just three transport licenses and about thirty preliminary approvals, leaving microbusinesses “totally stuck” and early shops like Voyager Cannabis Co. in Mankato and MN Grass Hero in Rice unable to stock basic flower, pre-rolls, or carts. The state tried to ease the crunch with a 90-day memo letting licensees haul their own product to testing labs, but the relief stops there, and the underlying rules still demand a $300,000 cargo bond and at least $1 million in liability coverage that feels sized for “the big people,” not a $25,000 harvest. Owners now face choices like paying $5,000 a month for an empty dispensary rather than risk losing a capped local license, hoping product will finally arrive by March. If OCM cannot bridge the gap between its security expectations and what small operators can realistically finance, Minnesota’s rollout will tilt toward the well-capitalized and leave independent shops as the latest case study in how a cautious framework can quietly pick winners. (MinnPost)
Telehealth rules that were meant to widen access during the pandemic have created a lane for high-volume prescribing of tightly controlled medicines, including medicinal cannabis. The Age traces how online clinics and subscription platforms stitched together bulk-billed consults, offshore call centers, and compliant prescribers into a pipeline where patients can move from questionnaire to couriered product with minimal friction. Regulators now warn that this model blurs the line between clinical care and mail-order commerce, especially when prescribing decisions lean on templated notes and brief video calls. The political tension sits between regional access arguments and a growing unease that telehealth has become a back door around the safeguards once built into in-person specialist care. How Canberra chooses to close or narrow that loophole will decide whether medicinal cannabis keeps riding the same rail as weight-loss drugs and ADHD scripts or is pulled back toward a slower, more traditional channel. (The Age)
A lender in New Jersey just learned that a cannabis borrower’s breach-of-contract suit can survive the first swing at dismissal. Law360 reports that the finance company is accused of blocking a refinancing and then declaring default when the parties could not close new terms, and the judge found those allegations plausible enough to move forward. The opinion treats the loan documents as ordinary commercial paper, not disposable because the underlying business handles federally illegal product. That stance forces private credit funds to assume their covenants and side letters may be read line by line in open court. The next wave of term sheets will reveal who is adjusting to that reality and who is still drafting as if illegality alone can rescue a bad workout strategy. (Law360)
Justice Cannabis and Advanced Flower Capital are now litigating each other in federal court like any other borrower and lender locked in a high-yield dispute. USA Herald notes that Judge Zahid Quraishi refused to toss Justice’s claim that AFC fabricated a default to grab almost two million dollars, even as AFC presses its own case against the company’s owners. A prior injunction already blocks AFC from seizing key assets while the merits play out, which keeps the company operating as the paperwork is tested. The opinion does not pick sides on who misused funds, yet it confirms that cannabis credit agreements are fully litigable commercial instruments. Quietly, that pushes both borrowers and funds to assume that a federal judge will treat their term sheets the way a chancery court treats any other complex finance deal. (USA Herald)
New York’s Office of Cannabis Management is asking a federal judge to treat a local town’s zoning code as preempted by state cannabis law, arguing the code effectively shuts licensed businesses out of town limits. The filing tells the court that state lawmakers already set the balance between local input and statewide access, and that municipalities cannot use land-use rules as a backdoor ban after missing the formal opt-out window. That move pulls a common tactic into the spotlight, since many towns have relied on setback rules, narrow districts, or “character” standards to stall dispensaries without saying no outright. If the court sides with OCM, local officials who built quiet vetoes into their zoning maps may have to choose between rewriting their codes or defending them head-on against state policy. (Law360)
A former supervisor at New Jersey cannabis manufacturer Kushi Labs LLC is asking a federal judge to cut back the company’s trade secrets lawsuit that accuses her of siphoning confidential materials to a rival. Her bid targets parts of the complaint she says sweep in ordinary know-how and overstate what counts as protectable information in a crowded infused-products market. The motion comes after Kushi already dropped the competitor from the case and chose to focus its claims on ex-employees who allegedly walked sensitive files out the door. The fight now turns on how tightly courts will police the boundary between a real trade secret and the kind of operational knowledge any logistics manager carries when they leave. (Law360)
Kyrsten Sinema is walking psychedelics reform straight into the offices of HHS Secretary RFK Jr. and Veterans Affairs Secretary Doug Collins. She describes both as receptive to therapies like ibogaine for veterans and calls this a magical, unique time to move policy. Her interview points to roughly a dozen VA trials, including MDMA-assisted therapy at the Bronx VA, which moves the issue from slogans into budgets and protocols. Sinema also sketches a coalition where conservative veterans and pastors frame psychedelics as a tool for trauma treatment while parts of the center-left worry about the optics. If that coalition holds, future guidance could look less like a culture-war statement and more like a veteran-focused health policy with unusually broad cover.(Marijuana Moment)
Mikie Sherrill’s transition team has left a text box open for anyone who wants to shape New Jersey’s next four years of cannabis policy. Heady NJ reports that advocates are flooding the survey with calls for home grow, which still sits as a felony and requires legislative action rather than a Cannabis Regulatory Commission rule tweak. Submissions also raise pricing, quality, and the Social Equity Excise Fee as small operators warn that higher wholesale taxes either bleed margins or land on consumers. The responses will feed into Action Teams and an Interdisciplinary Task Force, turning well-argued themes into early briefing book material. Stakeholders who can translate their wish lists into specific, enforceable asks now are more likely to see those ideas appear in bill drafts and budget riders later. (Heady NJ)
Like Moneyball for Stocks
The data that actually moves markets:
Congressional Trades: Pelosi up 178% on TEM options
Reddit Sentiment: 3,968% increase in DOOR mentions before 530% in gains
Plus hiring data, web traffic, and employee outlook
While you analyze earnings reports, professionals track alternative data.
What if you had access to all of it?
Every week, AltIndex’s AI model factors millions of alt data points into its stock picks.
We’ve teamed up with them to give our readers free access for a limited time.
The next big winner is already moving.
Past performance does not guarantee future results. Investing involves risk including possible loss of principal.
The deeper pattern behind today’s moves — and why it matters next.
Courts And Legislatures Are Closing Cannabis Gray Zones
🧾 Context: Over the past year, three very different forums have tightened some of the loosest seams in cannabis: a federal courtroom in New Jersey, town halls in New York, and the Capitol in Texas. In Hayden Gateway LLC v. Advanced Flower Capital Inc., a $75 million credit fight over Justice Cannabis produced a preliminary injunction that froze AFC’s ability to sweep accounts, based in part on an alleged oral “Reopening Agreement” and a pattern of covenant waivers. The judge later refused to dismiss the case, so contract and lender-liability theories continue with an appeal to the Third Circuit running in the background. In New York, courts and the Office of Cannabis Management have treated Riverhead’s 2,500 foot buffers, corridor frontage rules, and similar spacing tactics as preempted by MRTA, striking them in cases like Tink & E. Co. and Stark Enterprises and reinforcing that view through an OCM Advisory Opinion and a Cannabis Control Board vote that nullifies comparable ordinances statewide. Texas took a legislative route, expanding its Compassionate Use Program from 3 to 15 dispensing organizations, adding conditions such as chronic pain and traumatic brain injury, authorizing patches and vaporizers, and writing direct preemption language that blocks local governments from prohibiting low-THC activity.
🔎 What It Signals: These moves pull cannabis deeper into ordinary public-law and commercial frameworks. In Hayden Gateway, the court treated cannabis finance like any other complex lending relationship and signaled that “no oral modification” clauses, default letters, and chief restructuring officer conduct all sit within reach of waiver, novation, and bad-faith arguments when a borrower claims the lender engineered the crisis. New York’s preemption fights tell municipalities that opting in carries real obligations, and that zoning cannot function as a quiet veto once the legislature has set the balance between local input and statewide access. Texas’s legislation pushes in the same direction from another angle, instructing regulators to stand up at least 9 new providers by December and 3 more by April 1, 2026 and treating low-THC access as a statewide health program with defined products, conditions, and agency timelines. Across all three examples, risk begins to live less in personal relationships and side conversations and more in the text of the statute, the zoning map, and the loan history that a judge or regulator can defend in public.
🧠 THC Group Take: Why does any of this matter? The early days of creative rulemaking and figuring it out as you go are now giving way to structure and tradition. In New Jersey, that means borrowers and lenders can no longer treat side conversations, oral reopeners, and CRO improvisation as private territory; those choices now live in a world where a federal judge will read the emails, line up the covenants, and decide who changed the deal in practice. In New York, it means site selection, lease strategy, and local politics all need to assume that MRTA preemption has teeth, and that clever setbacks or corridor rules are more likely to end up as bad exhibits than enduring shields. In Texas, it means low-THC operators gain a larger, preempted footprint that looks more like a real health program, which will invite comparisons to mainstream clinical standards instead of keeping them in a political novelty category. These are early, concrete answers to the questions your lawyers, bankers, and local partners will be arguing in every new market, and the teams that absorb those answers now will spend less time paying to learn them the hard way.
From the hearing room to the comment section — we’re watching it all.
🧪 A German trial followed 166 stressed university students for 30 days and found that low-dose CBD oil and a placebo oil both reduced stress and depressive symptoms more than no treatment, with no meaningful difference between the two. It is a tidy reminder that at the doses most “chill” products actually deliver, belief, ritual, and branding can do as much work as the cannabinoid itself. (Cannabis Science and Technology)
👥 An MMJDaily feature on greenhouse operations argues that once you have reasonable genetics and infrastructure, the biggest swings in yield and quality come from how well-trained and engaged the cultivation team is. Turnover and thin training budgets eventually show up as uneven canopies, missed problems, and sloppier compliance long before they show up as a failed test result. (MMJDaily)
🍺 A Cannabis Industry Journal piece looks at how breweries that survived the craft beer shakeout used automation to keep flavor and identity while tightening consistency and throughput. The lesson for cannabis is that robots, conveyors, and real-time data are turning into the tools that protect “craft” from human error rather than threats to it. (Cannabis Industry Journal)
🌐 A WIPO decision over the domain sipmamas.com found that a hemp drinks company’s UDRP complaint crossed the line into reverse domain name hijacking after it tried to use a recently acquired trademark to grab a domain that had been used in good faith for infused beverages. It is a quiet warning that shortcut domain plays can leave a public paper trail that looks worse than the original dispute. (Domain Name Wire)